KD

Kyndryl is a genuine deep-value turnaround story trading at a fraction of sales (P/S 0.2x) and 13.2x earnings. After four years of bleeding (revenue $18.7B→$15.1B, cumulative losses topping $4B), the top line has finally flattened (FY2026 revenue +0.2%) and adjusted EBITDA has risen three straight years ($2,367M→$2,516M→$2,672M per MD&A). Operating cash flow of $948M against $608M capex leaves ~$340M of free cash, and management is leaning into the depressed stock — repurchasing 11.6M shares for $304M and adding $400M of new authorization in Nov 2025. The reported -21% net income drop is largely optical: it laps a $138M after-tax one-time gain on the FY2025 Canada SIS sale, while underlying efficiency work and growth in Kyndryl Consult and hyperscaler revenue continue. On the numbers alone this looks like a buy.

But the filing language changes the picture decisively. The MD&A discloses an ongoing SEC Division of Enforcement investigation into the Company's 'cash management practices, related disclosures, the efficacy of the Company's internal control over financial reporting,' alongside admitted material weaknesses in ICFR. When the integrity of the financial statements themselves is under federal investigation, every figure I would otherwise lean on carries an asterisk — and the outcome is unknowable. The market clearly agrees: the company's own buyback table shows it paying $25.13/share in January 2026, then $13.98 in February and $12.71 in March, a ~50% collapse in a single quarter that maps onto these disclosures.